Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (AORT) pioneers life-saving medical devices for aortic disease treatment, serving cardiac and vascular specialists worldwide. This dedicated news hub provides investors and medical professionals with timely updates on company developments, clinical advancements, and strategic initiatives.
Access official press releases, earnings reports, and regulatory updates in one centralized location. Track innovations across Artivion's core product lines including aortic stent grafts, surgical sealants, and implantable tissues. Our curated news collection helps stakeholders monitor clinical trial progress, partnership announcements, and market expansion efforts.
Key updates include FDA clearances, international regulatory milestones, and peer-reviewed study results from ongoing trials. Discover how Artivion's technologies continue to reshape treatment protocols in complex cardiovascular surgeries through verified clinical outcomes and surgeon testimonials.
Bookmark this page for continuous access to verified information about AORT's medical advancements. Check regularly for new developments impacting the future of aortic disease management and surgical innovation.
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company specializing in aortic disease, has announced the release date for its second quarter 2024 financial results. The results will be made public on Thursday, August 8, 2024, after market close. Following the release, the company will host a teleconference call and live webcast at 4:30 p.m. ET to discuss the results and conduct a Q&A session led by Pat Mackin, Chairman, President and CEO of Artivion.
Interested parties can access the live teleconference by dialing 201-689-8261 shortly before 4:30 p.m. ET. A replay will be available approximately one hour after the event. The live webcast and replay can be accessed through the Investors section of Artivion's website at www.artivion.com.
Artivion has revised its agreements with Endospan, providing up to $25 million in debt financing to assist in obtaining FDA approval for the NEXUS Stent Graft System. The upfront payment for a potential purchase of Endospan has been reduced to $135 million, inclusive of loan offsets, and the $100 million minimum earnout has been eliminated. NEXUS offers a minimally invasive treatment for aortic arch disease, targeting a $600 million annual global market. Artivion retains the option to acquire Endospan within 90 days of NEXUS FDA approval, with terms allowing for up to $12.5 million in equity as part of the payment.
Artivion, Inc. (NYSE: AORT) reported strong first quarter 2024 financial results with revenue of $97.4 million, an increase of 17% on a GAAP basis. Net income was $7.5 million, and non-GAAP adjusted EBITDA increased by 60%. The company revised its FY24 revenue guidance to 9-12% growth. The On-X aortic valve post-market clinical study showed promising results, lowering the risk of major bleeding by 87%. Artivion raised the lower end of its revenue guidance for 2024 and expects non-GAAP adjusted EBITDA to increase by 26-34% compared to 2023.
Artivion, Inc. (NYSE: AORT) announced new clinical data for On-X Aortic Heart Valve and AMDS at the 104th AATS Annual Meeting. 5-year real-world safety and efficacy data from On-X Aortic Valve show better patient outcomes than predicted. AMDS PERSEVERE Trial data demonstrate positive aortic remodeling outcomes. On-X Aortic Valve remains safe with low-dose warfarin. AMDS prevents DANE tears and induces positive aortic remodeling.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
